Increasing evidence suggests that the trajectory of Alzheimer’s disease (AD) pathologies, such as amyloid and tau, differ between the sexes.
Objective
Given the higher susceptibility of females to dementia, we aimed to investigate the sex differences in the primary accumulation of tau and its subsequent spread to later cortical brain regions.
Methods
We included 315 participants in this study: 221 cognitively unimpaired individuals with normal amyloid (n = 140, A- CU) or abnormal amyloid (n = 81, A+ CU), and 94 cognitively impaired individuals with abnormal amyloid (A+ CI). Each individual received two to six tau positron emission tomography (PET) scans using the [18F]-Flortaucipir (FTP) tracer. Linear regression analyses were performed to assess sex-specific tau spreading throughout the Braak stages among three clinical groups.
Results
The median (interquartile range) age of all samples was 73.5 (68 to 78.2) years. In total, 170 participants (54%) were female. In the A+ CU group, females exhibited higher tau-PET SUVR levels in all Braak I, III-IV, and V-VI. We found that the spreading pattern of tau may vary by sex and AD stages. In the A+ CI individuals, there was an observed interaction between the female sex and baseline tau SUVRs in Braak stages III-IV (p < 0.0001 and Bonferroni-corrected p < 0.0023), affecting longitudinal accumulation of tau in later Braak stages V-VI.
Conclusions
Our findings found a sex-specific pattern of tau spreading from Braak stages III-IV to V-VI in A+ CI older adults. This disadvantage may indicate that females might experience faster tau spreading and quicker disease progression when the condition develops to more advanced disease stages.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
2.
JackCR, Jr., AndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
3.
WangXYeTZhouWZhangJ.Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. Alzheimers Res Ther2023; 15: 57.
4.
SchöllMLockhartSNSchonhautDR, et al.PET imaging of tau deposition in the aging human brain. Neuron2016; 89: 971–982.
5.
MahamanYAREmbayeKSHuangF, et al.Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention. Ageing Res Rev2022; 74: 101544.
6.
MoscosoAGrotheMJAshtonNJ, et al.Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain2021; 144: 325–339.
7.
MatthewsDCKinneyJWRitterA, et al.Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients. Alzheimers Dement(N Y)2024; 10: e12490.
8.
YauWWShirzadiZYangHS, et al.Tau mediates synergistic influence of vascular risk and Aβ on cognitive decline. Ann Neurol2022; 92: 745–755.
9.
Pichet BinetteAFranzmeierNSpotornoN, et al.Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. Nat Commun2022; 13: 6635.
10.
BraakHBraakE.Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
11.
CaiYDuJLiA, et al.Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer's disease. Alzheimers Res Ther2023; 15: 30.
12.
BraakHAlafuzoffIArzbergerT, et al.Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol2006; 112: 389–404.
13.
BraakHThalDRGhebremedhinE, et al.Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol2011; 70: 960–969.
14.
MarquiéMSiao Tick ChongMAntón-FernándezA, et al.[F-18]-AV-1451binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol2017; 134: 619–628.
15.
GattoRGCarlosAFReichardRR, et al.Comparative assessment of regional tau distribution by Tau-PET and Post-mortem neuropathology in a representative set of Alzheimer's & frontotemporal lobar degeneration patients. PLoS One2023; 18: e0284182.
16.
SchöllMOssenkoppeleRStrandbergO, et al.Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain2017; 140: 2286–2294.
17.
GattoRGMeadeGDuffyJR, et al.Combined assessment of progressive apraxia of speech brain microstructure by diffusion tensor imaging tractography and multishell neurite orientation dispersion and density imaging. Brain Behav2024; 14: e3346.
18.
Singleton EH, Mattsson-Carlgren N, Pichet Binette A, et al. Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer's disease. Alzheimers Dement2025; 21: e70435.
19.
WegmannSBennettREDelormeL, et al.Experimental evidence for the age dependence of tau protein spread in the brain. Sci Adv2019; 5: eaaw6404.
20.
de CalignonAPolydoroMSuárez-CalvetM, et al.Propagation of tau pathology in a model of early Alzheimer's disease. Neuron2012; 73: 685–697.
21.
WangXYeTZhouWZhangJ.Association of distinct initial β-amyloid levels with tau pathology expansion beyond the entorhinal cortex. Neurology2025; 105: e214041.
22.
SmithRStrandbergOMattsson-CarlgrenN, et al.The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain2020; 143: 3805–3815.
23.
BuckleyRFScottMRJacobsHIL, et al.Sex mediates relationships between regional tau pathology and cognitive decline. Ann Neurol2020; 88: 921–932.
24.
DigmaLAMadsenJRRissmanRA, et al.Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Commun2020; 2: fcaa025.
25.
BuckleyRFMorminoECRabinJS, et al.Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol2019; 76: 542–551.
26.
OveisgharanSArvanitakisZYuL, et al.Sex differences in Alzheimer's disease and common neuropathologies of aging. Acta Neuropathol2018; 136: 887–900.
27.
WangXSundermannEEBuckleyRFBanksSJ.Sex differences in the association between tau PET and cognitive performance in a non-Hispanic White cohort with preclinical AD. Alzheimers Dement2024; 20: 25–33.
28.
Arenaza-UrquijoEMBoyleRCasalettoK, et al.Sex and gender differences in cognitive resilience to aging and Alzheimer's disease. Alzheimers Dement2024; 20: 5695–5719
29.
WangXYeTZhouWZhangJ.Sex-specific association of depressive symptom trajectories with cognitive decline and clinical progression in mild cognitive impairment. Alzheimers Dement2025; 21: e70548.
30.
WangYTTherriaultJServaesS, et al.Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females. Brain2024; 147: 1497–1510.
31.
WangXBroceIDetersKD, et al.Identification of sex-specific genetic variants associated with tau PET. Neurol Genet2022; 8: e200043.
32.
JackCR, Jr., WisteHJSchwarzCG, et al.Longitudinal tau PET in ageing and Alzheimer's disease. Brain2018; 141: 1517–1528.
BeckettLADonohueMCWangC, et al.The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement2015; 11: 823–831.
39.
JackCR, Jr., WisteHJWeigandSD, et al.Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement2017; 13: 205–216.
40.
BakerSLMaassAJagustWJ.Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief2017; 15: 648–657.
41.
ChoHChoiJYHwangMS, et al.In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol2016; 80: 247–258.
42.
MarquiéMNormandinMDVanderburgCR, et al.Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol2015; 78: 787–800.
43.
RoyseSKMinhasDSLoprestiBJ, et al.Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther2021; 13: 99.
44.
LandauSMMintunMAJoshiAD, et al.Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol2012; 72: 578–586.
45.
KlunkWEKoeppeRAPriceJC, et al.The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement2015; 11: 1–15.e11-14.
46.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014.
47.
PernegerTV.What's wrong with Bonferroni adjustments. BMJ1998; 316: 1236–1238.
48.
DesikanRSSégonneFFischlB, et al.An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage2006; 31: 968–980.
49.
VisserDVerfaillieSCJBoschI, et al.Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study. Eur J Nucl Med Mol Imaging2023; 50: 2409–2419.
50.
SundermannEEBiegonARubinLH, et al.Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurology2016; 86: 1368–1376.
51.
DumitrescuLBarnesLLThambisettyM, et al.Sex differences in the genetic predictors of Alzheimer's pathology. Brain2019; 142: 2581–2589.
52.
FerrettiMTIulitaMFCavedoE, et al.Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol2018; 14: 457–469.
53.
VegetoEVillaADella TorreS, et al.The role of sex and sex hormones in neurodegenerative diseases. Endocr Rev2020; 41: 273–319.
54.
BarkerRMChambersAKehoePG, et al.Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease. Clin Sci (Lond)2024; 138: 1357–1369.
55.
ZiontzJHarrisonTMFonsecaC, et al.Connectivity, pathology, and ApoE4 interactions predict longitudinal tau spatial progression and memory. Hum Brain Mapp2024; 45: e70083.
56.
KochGCasulaEPBonnìS, et al.Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. Brain2022; 145: 3776–3786.
57.
LeHLuiFLuiMY.Aphasia. StatPearls. Treasure Island (FL): StatPearls Publishing LLC., 2025.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
